What Key Growth Drivers Are Shaping The Cytokine Release Syndrome Management Market Forecast Toward $30.48 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Cytokine Release Syndrome Management Market Be Worth By 2029?
The market for managing cytokine release syndrome has seen robust growth in the past few years. It is projected to expand from $22.32 billion in 2024 to $23.76 billion in 2025, registering a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the historic period include heightened healthcare spending, increased awareness, lifestyle changes, high disposable income, the embrace of personalized medicine techniques, and the growing utilization of targeted therapies.
Over the coming years, the cytokine release syndrome management market is projected to experience substantial growth. The market is set to rise to $30.48 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%. The expansion in the predicted period can be attributed to the growing need for diagnostic tools and treatments, increased governmental funding, mounting demand for effective therapies, a burgeoning aging demographic, and proliferating efforts by both public and private establishments. Major trends expected during this forecast period encompass minimally invasive breast biopsy tools, alliances and partnerships, residential antibiotic infusion services, the emergence of innovative drug delivery systems, and the implementation of electronic health records in infection monitoring.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
What Market Forces Are Contributing To The Growth Of The Cytokine Release Syndrome Management Market?
The cytokine release syndrome management market is set for expansion due to the growing implementation of targeted therapies. These therapies, which work by disrupting the molecular targets that foster tumor growth, are instrumental in restraining cancer proliferation while concurrently mitigating damage to healthy cells. This approach enhances the effectiveness of treatment while lowering the side effects commonly associated with conventional therapies. In order to maximize the benefits of targeted therapies, managing cytokine release syndrome, a condition characterized by severe inflammatory reactions, is vital. This improves the safety and efficiency of treatments like CAR-T cell therapy and immune checkpoint inhibitors. As an illustration, the American Society of Gene and Cell Therapy reported in January 2024 that the count of gene therapies undergoing Phase III clinical trials saw a 10% rise in the fourth quarter of 2023, the first surge of this kind since the third quarter of 2022. As a result, the escalating utilization of targeted therapies is a key driver of growth in the cytokine release syndrome management market.
Which Segments Define The Structure Of The Cytokine Release Syndrome Management Market?
The cytokine release syndrome managementmarket covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications
3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration
4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies
2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors; Bruton’s Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents
5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support
What Strategic Shifts And Innovations Are Influencing The Cytokine Release Syndrome Management Market?
Leading corporations in the cytokine release syndrome management market are honing their focus on performing clinical trials for the creation of innovative treatments. These include host-directed small molecule drugs, which aim to manipulate the immune response and diminish the intensity of cytokine storms, without endangering the body’s capacity to combat infections or cancer. A host-directed small molecule drug is a lower molecular weight compound that focuses on the host’s immune signaling pathways, alleviating excessive cytokine production, and therefore aiding in controlling cytokine release syndrome (CRS) by stopping overactivation of the immune system. In April 2025, CytoAgents Inc., an American biotech firm, revealed the successful conclusion of the initial dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681. This is a host-directed small molecule drug engineered to both prevent and treat CRS in patients undergoing CAR T-cell therapy. The experimental treatment displayed a positive safety profile, with no dose-limiting toxicities or interference with CAR T-cell effectiveness. This trial is being carried out with a rolling six dose-escalation design to evaluate CTO1681’s safety, tolerability, and preliminary efficacy, while also determining the recommended phase 2 dose.
Which Firms Are Making The Biggest Impact In The Cytokine Release Syndrome Management Market?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Cytokine Release Syndrome Management Market In The Coming Years?
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Management Market 2025, By The Business Research Company
Hepatorenal Syndrome Treatment Global Market Report 2025
Myelodysplastic Syndrome Drugs Global Market Report 2025
Dry Eye Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
